Monitoring of compliance utilizing tramadol
Detection and confirmation of the illicit use of tramadol
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
TraMADol
Ultram
Ultram ER
Ultracet
ConZip
Urine
Supplies: Sarstedt 5 mL Aliquot Tube (T914)
Collection Container/Tube: Plastic urine container
Submission Container/Tube: Plastic vial, 5 mL
Specimen Volume: 1 mL
Collection Instructions:
1. Collect a random urine specimen.
2. No preservative.
Additional Information:
1. No specimen substitutions.
2. STAT requests are not accepted for this test.
3. Submitting <1 mL will compromise our ability to perform all necessary testing.
If not ordering electronically, complete, print, and send a Therapeutics Test Request (T831) with the specimen.
0.5 mL
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability. |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Urine | Refrigerated (preferred) | 14 days | |
Ambient | 14 days | ||
Frozen | 14 days |
Monitoring of compliance utilizing tramadol
Detection and confirmation of the illicit use of tramadol
Tramadol, a centrally acting opioid analgesic, is utilized in the treatment of moderate to moderately severe pain. Tramadol acts as an opiate agonist through the binding of the parent drug and its O-desmethyl (M1) metabolite to mu-opioid receptors and through the weak inhibition of norepinephrine and serotonin reuptake. The active metabolite, O-desmethyltramadol, is a considerably more potent mu-opioid receptor agonist than its parent drug. In urine, approximately 30% of tramadol is excreted as unchanged drug, while approximately 60% is excreted as metabolites (N- and O-desmethyltramadol). The half-life of tramadol and O-desmethyltramadol is approximately 7 hours.
The presence of tramadol or O-desmethyltramadol levels of 25 ng/mL or higher is a strong indicator that the patient has used tramadol.
Urine concentrations do not correlate well with serum drug levels and are not intended for therapeutic drug management.
Results are intended to be interpreted by a physician or health care professional. This test is not intended for use in employment-related testing
1. Grond S, Sablotzki A: Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923
2. Dayer P, Collart L, Desmeules J: The pharmacology of tramadol. Drugs. 1994;47(Suppl 1):3-7
3. Langman LJ, Bechtel L, Meier BM, Holstege CP: Clinical toxicology. In: Rifai N, Horwath AR, Wittwer CT, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 6th ed. Elsevier; 2018:832-887
Isotopically labeled tramadol and O-desmethyltramadol are added to the sample as internal standards. The sample is then diluted with deionized water and the analytes are separated by liquid chromatography and then quantified by mass spectrometry using multiple reaction monitoring.(Patel BN, Sharma N, Sanyal M, Shrivastav PS: An accurate, rapid and sensitive determination of tramadol and its active metabolite O-desmethyltramadol in human plasma by LC-MS/MS. J Pharm Biomed Anal. 2009 Feb 20;49[2]:354-366)
Tuesday
This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.
80373
G0480 (if appropriate)
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
TRAM | Tramadol and Metabolite, U | 100734-3 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
35914 | Tramadol | 17719-6 |
35915 | O-desmethyltramadol | 92639-4 |
Change Type | Effective Date |
---|---|
Test Changes - Specimen Information | 2021-10-25 |